Merk (MRK) Earnings Report Q2 2025
On Tuesday, April 8, 2025, Merk & Company Signez on the floor of New York Stock Exchange (NYSE) in New York, the US.
Michael Nagas | Bloomberg | Getty
Merk It is said on Tuesday that the cost of $ 3 billion will be reduced by the end of 2027 to support a new product launch and its drug pipeline.
In 228, Merk’s efforts are made by preparation for the Revenue Loss off due to the upcoming patent expiration at Blockbuster Cancer Kitruda. It has also come as President Donald Trump’s pharmaceutical manufacturer brackets. Planned rates on imported pharmaceuticals imported in the United States, Who motivated Merk and other companies to invest billions in the United States to boost their manufacturing footprints in the United States
“Today we have announced a multi-year optimization initiative that will reduce the growing aire of our new growth drivers from more mature areas of our business, enable our portfolio transformation, and run the next chapter of our productive, innovative growth,” Merk CEO Rob Davis said.
As part of the effort, Merk in July approved the new reconstruction program, which will eliminate some administrative, sales and research and development conditions. The company will also reduce its global real estate position and continue its production network.
Merk has expected action under the restructuring program. Annual cost savings will produce about $ 1.7 billion, most of which will start at the end of the end of 227.
The company is expected to be approximately $ 3 billion in the premises related to the restructuring program. In his second quarter, Merk recorded 6649 million charges related to the program.
Also on Tuesday, Merk recorded revenue in the second quarter, which reduced the Wall Street estimates. Metrics lost expectations for the first time since April 2021.
While Kitruda sales are increasing during this period, Merk continued to face China’s sales in China’s sales, which prevents cancer from HPV, the most common sexually transmitted infection in the United States.
In February, Merk announced the decision to stop the shipment of the guardil in China from that month and go in the middle of at least 2025. In a comment made on Tuesday, Merk CFO Caroline Lichfield said the company would not resume China at a minimum of 225, stating that the list is high and the demand is still soft.
The company also narrated its entire year’s guidance. Merk is now expected to earn a 2025 adjustable earnings that will come from $ 8.87 to $ 8.97 per share. This compares the previous view of his previous share of 82 8.82 to $ 8.97.
Merk is expected to receive revenue for this year. The revenue of $ 3 billion to 3 billion to $ 3 billion, it has reduced from the previous guidance.
Here is what Merk said in the second quarter compared to the expectation of Wall Street, according to a survey of LSEG analysts:
- Per share earnings: Adjusted $ 2.13. That figure cannot be compared to estimates of $ 2.01.
- Revenue: .8 15.81 billion Vs. Expected to $ 15.89 billion
Merk said that Trump has an estimated result of $ 200 million in the previously announced Million relevant to the rates implemented till date. The company said in April Expected rate fee Mainly reflects the levy between the US and China, but the sector-specific pharmaceutical tariffs have not been calculated.
This point of view also includes a one-time fee related to the company’s license agreement of the company’s company’s license, but not in the acquisition of the recently announced Verona Farm.
The company posted a net income of $ 1.43 billion or $ 1.76 per share in the quarter. During the year, the net income of $ 1.46 billion or $ 1.14 per share is compared to the year.
Excluding the cost of acquisition and restructuring, Merk earned $ 2.13 per share in the second quarter. It includes 7 Cent charges per share with Hengroi Pharma to close the license agreement.
Merk earned $ 1.8.8 billion in the quarter.
Pharmaceutical, animal health sales
Marsk’s pharmaceutical unit, which has developed a variety of drugs, booked revenue of $ 14.05 billion in the second quarter. It is 2% down to the same period a year ago.
Kitruda has reported $ 7.96 billion this quarter, which has only increased by 9% compared to the early period of the year.
The company said the increase in the previous phase cancer and the increase in the demand for metastatic cancer drugs, which spread to other parts of the body, has increased. According to the Street Account estimates, analysts expected the drug sales to $ 7.9 billion.
The Guardian sold $ 1.13 billion in this quarter. Due to low demand in China, 55% below the same period a year ago. The guardian expected the analyst to book a $ 1.3333 billion, according to the Street Account estimates.
Chinese markets make the international revenue of most blockbusters shots. Merk hopes that men between the ages of 9 to 26 in China will help to increase the vaccine with the garden’s approval.
In the second quarter, sales of gardens in the United States increased by 2%.
Meanwhile, Merk’s new drug winterware, which is used to treat rare, deadly lungs, recorded a sales of $ 6336 million in the quarter. According to the Street Account estimates, analysts had expected to bring the drug 424.7 million.
Animal Health Division of Merk, which develops dogs, cats and cattle vaccines and drugs, has sold about $ 1.6565 billion, which increases by 5% over the same period of the year. The company said that the high demand for livestock products and sales in the Aqua business of the Aqua business obtained last year has led to this increase.
Post Comment